{"ticker": {"uuid": "6bb76c40-e04b-42bd-bab3-bac6593f357c", "symbol": "CGEM", "name": "Cullinan Oncology LLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cullinan CSO sells shares, exercises options | CGEM Insider Trading", "summary": "Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, executed an exercise-and-sell transaction. She sold 8,000 shares of common stock at a weighted average price of $17.82 per share under a pre-arranged Rule 10b5-1 trading plan and simultaneously exercised stock ", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-b77ba8f29cbb.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:11:41", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted", "summary": "A Form 144 filing by CGEM (Cullinan Therapeutics, Inc.) indicates a proposed resale of 8,000 shares of common stock from insider-related sources. This includes 4,000 shares from exercised stock options (dated 07/06/2026) and 4,000 shares from Restricted Stock Units (dated 02/22/2", "url": "https://www.stocktitan.net/sec-filings/CGEM/144-cullinan-therapeutics-inc-sec-filing-3c67b0fb0db9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:11:42", "published_display": "07 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cullinan Therapeutics, Inc. \u2013 NASDAQ:CGEM", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPSTVKT1E0Wkl3RzZVY0NkcWR0UGMySW0zbDUyWnN1aGZjWS1FV0dTa1JUdF9weHdKZVVLZnF0QkhVV2lsQ1VSdW9GMWU1VmI4emVDNUN4VTFBWGZtQkM2cU93TVJycV8waTFPc0tQWnFONTM3SWU5V3ZLWWdyU2h4Nkl6NnRianpubVJtb3Fna3RlaGRHNXhzUmNyUmpkUGtPQ3c?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T16:17:28+00:00", "published_display": "06 Jul 2026 16:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (CGEM) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, identifying a weak near-term sentiment but strong mid- and long-term outlook. It highlights a significant 53.2:1 risk-reward short setup and provides specific AI-generated trading strategies includi", "url": "https://news.stocktradersdaily.com/news_release/35/Why_CGEM_Price_Action_Is_Critical_for_Tactical_Trading_070626113001_1783351801.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T11:39:40", "published_display": "06 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEM - Cullinan Therapeutics Inc Latest SEC Filings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9Wa09peHM4dGRoY3VBamlWdFlzMHRtVFp6UnZTM2Itb0dVWWhrdkUtNm9FSzNJU1B0aU16Y1NoMnROUXJKUnhpVTBHMG1Fb1dKTDdaWkRENHFPZERWcF9pMl8zeTBpVUZw?oc=5", "source_name": "Finviz", "published_at": "2026-07-05T00:37:42+00:00", "published_display": "05 Jul 2026 00:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase", "summary": "Cullinan Therapeutics' CFO, Mary Kay Fenton, acquired 1,541 shares of company common stock through the 2021 Employee Stock Purchase Plan. The shares were purchased at $8.60 each, based on 85% of the closing price on January 2, 2026, for the period of January 1 to June 30, 2026. F", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-3bf374768061.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:58", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60", "summary": "Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, acquired 2,470 shares of common stock at $8.60 per share through the company's 2021 Employee Stock Purchase Plan. This routine transaction, which occurred between January 1 and June 30, 2026, increases her direct hol", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-48fa102eadbb.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:58", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 \u2013 DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine", "summary": "The EGFR-NSCLC market is projected to grow significantly, from USD 7.0 billion in 2025 to USD 16.0 billion by 2036, driven by targeted therapies and advancements in treatment. Key companies like AstraZeneca, J&J, and others are actively developing and launching therapies such as ", "url": "https://www.barchart.com/story/news/3046578/egfrnsclc-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2036-delveinsight-dizal-pharma-eli-lilly-cullinan-oncology-taiho-pharma-astrazeneca-jj-innovative-medicine", "source_name": "Barchart.com", "published_at": "2026-06-30T11:11:55", "published_display": "30 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com", "summary": "Cullinan Oncology (CGEM) stock recently hit a 52-week high of $17.97, reflecting a significant 127.68% increase over the past year. Despite an InvestingPro analysis suggesting potential overvaluation, the company, with a $1.1 billion market capitalization, continues to show stron", "url": "https://ng.investing.com/news/stock-market-news/cullinan-oncology-stock-hits-52week-high-at-1797-93CH-2570574", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T11:39:10", "published_display": "27 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data \u2013 Has The Bull Case Changed?", "summary": "Cullinan Therapeutics (CGEM) stock surged 31.0% after reporting positive Phase 1 data for its T cell engagers, CLN-978 and velinotamig, in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. This data indicates strong clinical responses and favorable s", "url": "https://www.sahmcapital.com/news/content/cullinan-therapeutics-cgem-is-up-310-after-autoimmune-t-cell-engager-data-has-the-bull-case-changed-2026-06-24", "source_name": "Sahm", "published_at": "2026-06-26T09:09:28", "published_display": "26 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (CGEM)", "summary": "This article provides an in-depth analysis of Cullinan Oncology Inc. (CGEM) using AI models to identify momentum shifts and suggest trading strategies. It highlights strong sentiment across all time horizons supporting an overweight bias and points out that resistance is being te", "url": "https://news.stocktradersdaily.com/news_release/39/Understanding_Momentum_Shifts_in_CGEM_062526102201_1782397321.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T10:22:00", "published_display": "25 Jun 2026 10:22", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Oncology stock hits 52-week high at $17.97", "summary": "Cullinan Oncology LLC's stock reached a 52-week high of $17.97, and is currently trading just 1% below this peak. The company has recently reported positive clinical trial data, received Orphan Drug Designation for CLN-049, and held its Annual Meeting of Stockholders. Analysts fr", "url": "https://m.uk.investing.com/news/stock-market-news/cullinan-oncology-stock-hits-52week-high-at-1797-93CH-4740849?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T07:11:24", "published_display": "24 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cullinan-therapeutics-cgem-27-1-090613388.html", "source_name": "Simply Wall St.", "published_at": "2026-06-23T09:06:13+00:00", "published_display": "23 Jun 2026 09:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) Citi\u2019s 2026 Virtual Oncology Leadership Summit Summary", "summary": "Cullinan Therapeutics discussed its pipeline strategy at Citi\u2019s 2026 Virtual Oncology Leadership Summit, highlighting T-cell engagers CLN-978 for autoimmune diseases and CLN-049 for AML as key catalysts for the year. The company aims for transformative potential with first-in-cla", "url": "https://quartr.com/events/cullinan-therapeutics-cgem-citi-s-2026-virtual-oncology-leadership-summit_Fk1FNul7", "source_name": "Quartr", "published_at": "2026-06-22T06:39:24", "published_display": "22 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant", "summary": "Cullinan Therapeutics director Andrew R. Allen was granted stock options for 21,781 shares of common stock with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the company's next annual meeting, provided his continued board service. Thi", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-b64171376790.html", "source_name": "Stock Titan", "published_at": "2026-06-19T05:10:15", "published_display": "19 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike", "summary": "Cullinan Therapeutics director Mary Thistle was granted 25,319 stock options with an exercise price of $13.55 per share. The options will vest in full by June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This grant is part of h", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-e7d51cd50047.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:20", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) grants director 25,319 stock options", "summary": "Cullinan Therapeutics (CGEM) director Anthony Rosenberg was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or at the company's next annual meeting, provided he continues his board service. The Form 4 fili", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-c17ed4adf0be.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:20", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options", "summary": "Cullinan Therapeutics director Mittie Doyle was granted 21,781 stock options at an exercise price of $13.55 per share. The options will vest in full on the earlier of June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This trans", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-967ea913abc1.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:20", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) director receives stock options for 25,319 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUXVUY3FSZ01lQ0g0X0ZuS2VkaXpPYTRpTXlYTHFtUVNjVUpGT0pqb05HQi1saEpOa3ZESmlpY2d5ZEE2YmhpZmNwdk5FcWtKNmtkbUdRSmhxNlgxeWhwYy1TTFd6SU9YNnlFd2R5UTcyNVk5WDQ2WUgzMUEyVFRkcjd2S2VSWktNLWFkTEpsZVBPRzJ3Vk1hZWE3VWVRbl9RRDJKeEo4OGJiVVNVd2x5R1JBOG1BMU9zb1o0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting", "summary": "Cullinan Therapeutics (NASDAQ: CGEM) shareholders elected two Class III directors for three-year terms, ratified KPMG LLP as the independent registered public accounting firm, and approved an advisory vote on executive compensation at their annual meeting. The biotech company has", "url": "https://ng.investing.com/news/sec-filings/cullinan-therapeutics-shareholders-elect-directors-and-approve-proposals-at-annual-meeting-93CH-2561721", "source_name": "Investing.com Nigeria", "published_at": "2026-06-17T16:39:35", "published_display": "17 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM)", "summary": "Cullinan Therapeutics director David D. Meek was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the date of the company's next annual meeting, contingent on his continued service as a director. This gr", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-9ec69de66175.html", "source_name": "Stock Titan", "published_at": "2026-06-17T10:11:04", "published_display": "17 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay", "summary": "Cullinan Therapeutics (NASDAQ: CGEM) shareholders held their Annual Meeting on June 16, 2026, where they elected two Class III directors, Nadim Ahmed and Stephen Webster, to three-year terms. They also ratified KPMG LLP as the independent registered accounting firm for 2026 and a", "url": "https://www.stocktitan.net/sec-filings/CGEM/8-k-cullinan-therapeutics-inc-reports-material-event-07fbcc8a3cd7.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:33", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (CGEM) Movement", "summary": "Cullinan Oncology Inc. (NASDAQ: CGEM) is showing weak near and mid-term sentiment but a strong long-term outlook, according to AI models. The article details three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss l", "url": "https://news.stocktradersdaily.com/news_release/40/Avoiding_Lag:_Real-Time_Signals_in_CGEM_Movement_061426091002_1781442602.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-14T09:10:00", "published_display": "14 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOamQtSnd6XzhTTmUwQmlPc2ZmV1VZUzVjbDRQUC15a3Fua0FVOE5zWk5VQmRQTHczbWJnTlBpSkF3RXZoblRsa2hNUUZFSEIzb3p1OWVYdVFkVWdPT08zbUhwbXRHR0FUN29TUlRKVU5hUjBYU3NNcTBjY2tiazh5bk84b0RCakUzWEdUNC1R?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Cullinan Therapeutics, Inc. Reports Material Event", "summary": "Cullinan Therapeutics (NASDAQ: CGEM) has reported early-stage clinical data for its T cell engager programs CLN-978 and velinotamig, targeting autoimmune diseases. CLN-978 showed robust efficacy, including remission in a rheumatoid arthritis patient, and velinotamig demonstrated ", "url": "https://www.stocktitan.net/sec-filings/CGEM/8-k-cullinan-therapeutics-inc-reports-material-event-f74cc68f68cd.html", "source_name": "Stock Titan", "published_at": "2026-06-11T01:40:29", "published_display": "11 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics reports promising autoimmune trial data", "summary": "Cullinan Therapeutics announced promising initial clinical data for its dual-targeting T-cell engager, CLN-978, showing its potential in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company reported clinical remissions and B-cell ", "url": "https://grafa.com/en/news/united-states/cgem-cullinan-immunology-data-2026", "source_name": "grafa.com", "published_at": "2026-06-10T15:38:51", "published_display": "10 Jun 2026 15:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cullinan-therapeutics-reports-early-positive-121201214.html", "source_name": "MT Newswires", "published_at": "2026-06-10T12:12:01+00:00", "published_display": "10 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan reports clinical data for autoimmune drug candidates", "summary": "Cullinan Therapeutics Inc. reported promising clinical data for two T cell engager drug candidates, CLN-978 and velinotamig, targeting autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis. Despite a recent stock decline, the company saw positive patient ", "url": "https://m.uk.investing.com/news/stock-market-news/cullinan-reports-clinical-data-for-autoimmune-drug-candidates-93CH-4721558?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-10T12:38:51", "published_display": "10 Jun 2026 12:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases", "summary": "Cullinan Therapeutics announced new clinical data from its T cell engager programs targeting CD19 (CLN-978) and BCMA (velinotamig) for autoimmune diseases. CLN-978 showed potential for immune reset and clinical remissions in systemic lupus erythematosus (SLE) and rheumatoid arthr", "url": "https://www.stocktitan.net/news/CGEM/cullinan-therapeutics-shares-new-clinical-data-across-its-portfolio-vfdmuw4ody73.html", "source_name": "Stock Titan", "published_at": "2026-06-10T11:10:44", "published_display": "10 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Shares New Clinical Data Across Its", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxQcG1LSHREWWRGQU9lZGxMTWF6dkMwNkNTcGthYUVpREI1dWIxU0wyUk9pU3hhX0wwOWxfcnVkVERNWnE4Sm9jVVVpNnNPTHF5VWx4TUp0VzVMVzI5clBJVGYydnNzVW9vcExyNkVhdlZjM0NfYzZveWU5TnlOUm5MVUQtY2NLdHpfb0dPb1hmUXNZZlJfQ01IVDBSdzR3Ql9zVEQ0MkY5eXg0bThaWUFsYWRnYWJQclh6WndaRTdUX2s0Z2J1VVFOZ2ZqbmxYM29CbzlzbWlpTnBoV05aaTZxTHpmRlVKRjB3NGZMV3hqWGctZm9aZ3A3WE44YzBIX0o1dkM0YUVzd0p0YjhoMEJIUzFWV3ZzZjJjVWVPaG1ScmxSaVd3S3ZvdmdaY3pQSHM3VWlDLVlRYkM?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data", "summary": "Cullinan Therapeutics reported initial Phase 1 data for CLN-978, a T cell engager, in treatment-refractory systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), showing meaningful clinical and biologic signals. In SLE, 71% of patients achieved a significant reduction ", "url": "https://www.stocktitan.net/sec-filings/CGEM/8-k-cullinan-therapeutics-inc-reports-material-event-0b963e9bf286.html", "source_name": "Stock Titan", "published_at": "2026-06-08T13:39:46", "published_display": "08 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress", "summary": "Cullinan Therapeutics presented initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress, demonstrating clinical benefit and remission in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The data showed deep, ", "url": "https://www.globenewswire.com/news-release/2026/06/06/3307681/0/en/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-t-cell-engager-at-the-eular-2026-congress.html", "source_name": "GlobeNewswire", "published_at": "2026-06-06T09:40:48", "published_display": "06 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in CGEM Response", "summary": "This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), identifying a near-term strong sentiment potentially shifting to neutral mid-term and positive long-term. It highlights an exceptional 63.5:1 risk-reward setup targeting a 16.9% gain with minimal risk and provides three", "url": "https://news.stocktradersdaily.com/news_release/1/Discipline_and_Rules-Based_Execution_in_CGEM_Response_060326074002_1780486802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-03T07:40:00", "published_display": "03 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEM - Cullinan Therapeutics Inc Stock Price and Quote", "summary": "Cullinan Therapeutics Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing oncology and immuno-oncology therapies. The article provides detailed financial data, analyst ratings, and a comprehensive list of recent company news and insider transactions, i", "url": "https://finviz.com/stock?t=CGEM", "source_name": "Finviz", "published_at": "2026-05-26T19:10:39", "published_display": "26 May 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cullinan-therapeutics-host-immunology-day-110000381.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:00:00+00:00", "published_display": "26 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Gets FDA Orphan Drug Designation for CLN-049 in Acute Myeloid Leukemia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cullinan-therapeutics-gets-fda-orphan-114216412.html", "source_name": "MT Newswires", "published_at": "2026-05-19T11:42:16+00:00", "published_display": "19 May 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cullinan-therapeutics-receives-fda-orphan-110000684.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We're Hopeful That Cullinan Therapeutics (NASDAQ:CGEM) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNWVlYcFJXTzB5QmdFZVYzZDdqYmpZSU81cEJXbXlMcG1mNzlXNVJud25oRWlWQTh6YmNKekdIUnBXZnB5ck9IbTBVYjZHN0lNMFhNNklqQU1BeUdaZkJPRFNhbXJRXzNBRlNIdmtKMUkyZmJVMmE4UFFaN2hQdWRLZDJsY0VaM1c0eVl5VlZHcmZOSEluX0RMMVNFRl9vUFQ2R0hiS1FoNUhRekI0NEE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOamdub0ZtNFF1cEhESEVyWkRjZmFvd0JlVjBBUmxWQ0pNZTFEVUNJMzJ3cDVBaVdGOHdybmlWcnNsTzk0Z1hucXFfcFVpVEctV1JCRFh2eWRkODN2UzJyN3N1VG96bFNmSUQ5b3d0YzVJcUhOV29JM3BMNDFIbHFjRnBRR29oVUJ3akthNGVOZzIyQQ?oc=5", "source_name": "Market source", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lynx1 capital buys Cullinan Therapeutics (CGEM) shares for $2.1m", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMHBJMlVIa1lDMVRLd0JnLU5iaGtqaGZGLTNVZVNiZV9UWDNHRF9TN1Fyeks4eHI1Y0h1M0xuR2w2V1NwNFpWWUJVelAyenRaaFJhSGk1WS13NmRRSlFaaUlReEVReXJ2Q0puMzhDZU5QQVQ0SEpOQjM2ZmhJMy05aEVZV0pVTEYyTXYwRjVRZ1NxOW5OLVhRX1AxZGdtX0V3SUlhNmJKZUp2MEhMSXlGQkNkaVA3a2ZZUjF1ZlFJbm40VzQ?oc=5", "source_name": "Investing.com", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cullinan CSO sells shares, exercises options | CGEM Insider Trading", "summary": "Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, executed an exercise-and-sell transaction. She sold 8,000 shares of common stock at a weighted average price of $17.82 per share under a pre-arranged Rule 10b5-1 trading plan and simultaneously exercised stock ", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-b77ba8f29cbb.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:11:41", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted", "summary": "A Form 144 filing by CGEM (Cullinan Therapeutics, Inc.) indicates a proposed resale of 8,000 shares of common stock from insider-related sources. This includes 4,000 shares from exercised stock options (dated 07/06/2026) and 4,000 shares from Restricted Stock Units (dated 02/22/2", "url": "https://www.stocktitan.net/sec-filings/CGEM/144-cullinan-therapeutics-inc-sec-filing-3c67b0fb0db9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:11:42", "published_display": "07 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cullinan Therapeutics, Inc. \u2013 NASDAQ:CGEM", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPSTVKT1E0Wkl3RzZVY0NkcWR0UGMySW0zbDUyWnN1aGZjWS1FV0dTa1JUdF9weHdKZVVLZnF0QkhVV2lsQ1VSdW9GMWU1VmI4emVDNUN4VTFBWGZtQkM2cU93TVJycV8waTFPc0tQWnFONTM3SWU5V3ZLWWdyU2h4Nkl6NnRianpubVJtb3Fna3RlaGRHNXhzUmNyUmpkUGtPQ3c?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T16:17:28+00:00", "published_display": "06 Jul 2026 16:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (CGEM) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, identifying a weak near-term sentiment but strong mid- and long-term outlook. It highlights a significant 53.2:1 risk-reward short setup and provides specific AI-generated trading strategies includi", "url": "https://news.stocktradersdaily.com/news_release/35/Why_CGEM_Price_Action_Is_Critical_for_Tactical_Trading_070626113001_1783351801.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T11:39:40", "published_display": "06 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEM - Cullinan Therapeutics Inc Latest SEC Filings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9Wa09peHM4dGRoY3VBamlWdFlzMHRtVFp6UnZTM2Itb0dVWWhrdkUtNm9FSzNJU1B0aU16Y1NoMnROUXJKUnhpVTBHMG1Fb1dKTDdaWkRENHFPZERWcF9pMl8zeTBpVUZw?oc=5", "source_name": "Finviz", "published_at": "2026-07-05T00:37:42+00:00", "published_display": "05 Jul 2026 00:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase", "summary": "Cullinan Therapeutics' CFO, Mary Kay Fenton, acquired 1,541 shares of company common stock through the 2021 Employee Stock Purchase Plan. The shares were purchased at $8.60 each, based on 85% of the closing price on January 2, 2026, for the period of January 1 to June 30, 2026. F", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-3bf374768061.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:58", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60", "summary": "Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, acquired 2,470 shares of common stock at $8.60 per share through the company's 2021 Employee Stock Purchase Plan. This routine transaction, which occurred between January 1 and June 30, 2026, increases her direct hol", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-48fa102eadbb.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:58", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 \u2013 DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine", "summary": "The EGFR-NSCLC market is projected to grow significantly, from USD 7.0 billion in 2025 to USD 16.0 billion by 2036, driven by targeted therapies and advancements in treatment. Key companies like AstraZeneca, J&J, and others are actively developing and launching therapies such as ", "url": "https://www.barchart.com/story/news/3046578/egfrnsclc-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2036-delveinsight-dizal-pharma-eli-lilly-cullinan-oncology-taiho-pharma-astrazeneca-jj-innovative-medicine", "source_name": "Barchart.com", "published_at": "2026-06-30T11:11:55", "published_display": "30 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com", "summary": "Cullinan Oncology (CGEM) stock recently hit a 52-week high of $17.97, reflecting a significant 127.68% increase over the past year. Despite an InvestingPro analysis suggesting potential overvaluation, the company, with a $1.1 billion market capitalization, continues to show stron", "url": "https://ng.investing.com/news/stock-market-news/cullinan-oncology-stock-hits-52week-high-at-1797-93CH-2570574", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T11:39:10", "published_display": "27 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data \u2013 Has The Bull Case Changed?", "summary": "Cullinan Therapeutics (CGEM) stock surged 31.0% after reporting positive Phase 1 data for its T cell engagers, CLN-978 and velinotamig, in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. This data indicates strong clinical responses and favorable s", "url": "https://www.sahmcapital.com/news/content/cullinan-therapeutics-cgem-is-up-310-after-autoimmune-t-cell-engager-data-has-the-bull-case-changed-2026-06-24", "source_name": "Sahm", "published_at": "2026-06-26T09:09:28", "published_display": "26 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (CGEM)", "summary": "This article provides an in-depth analysis of Cullinan Oncology Inc. (CGEM) using AI models to identify momentum shifts and suggest trading strategies. It highlights strong sentiment across all time horizons supporting an overweight bias and points out that resistance is being te", "url": "https://news.stocktradersdaily.com/news_release/39/Understanding_Momentum_Shifts_in_CGEM_062526102201_1782397321.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T10:22:00", "published_display": "25 Jun 2026 10:22", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Oncology stock hits 52-week high at $17.97", "summary": "Cullinan Oncology LLC's stock reached a 52-week high of $17.97, and is currently trading just 1% below this peak. The company has recently reported positive clinical trial data, received Orphan Drug Designation for CLN-049, and held its Annual Meeting of Stockholders. Analysts fr", "url": "https://m.uk.investing.com/news/stock-market-news/cullinan-oncology-stock-hits-52week-high-at-1797-93CH-4740849?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T07:11:24", "published_display": "24 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cullinan-therapeutics-cgem-27-1-090613388.html", "source_name": "Simply Wall St.", "published_at": "2026-06-23T09:06:13+00:00", "published_display": "23 Jun 2026 09:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) Citi\u2019s 2026 Virtual Oncology Leadership Summit Summary", "summary": "Cullinan Therapeutics discussed its pipeline strategy at Citi\u2019s 2026 Virtual Oncology Leadership Summit, highlighting T-cell engagers CLN-978 for autoimmune diseases and CLN-049 for AML as key catalysts for the year. The company aims for transformative potential with first-in-cla", "url": "https://quartr.com/events/cullinan-therapeutics-cgem-citi-s-2026-virtual-oncology-leadership-summit_Fk1FNul7", "source_name": "Quartr", "published_at": "2026-06-22T06:39:24", "published_display": "22 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant", "summary": "Cullinan Therapeutics director Andrew R. Allen was granted stock options for 21,781 shares of common stock with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the company's next annual meeting, provided his continued board service. Thi", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-b64171376790.html", "source_name": "Stock Titan", "published_at": "2026-06-19T05:10:15", "published_display": "19 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike", "summary": "Cullinan Therapeutics director Mary Thistle was granted 25,319 stock options with an exercise price of $13.55 per share. The options will vest in full by June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This grant is part of h", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-e7d51cd50047.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:20", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) grants director 25,319 stock options", "summary": "Cullinan Therapeutics (CGEM) director Anthony Rosenberg was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or at the company's next annual meeting, provided he continues his board service. The Form 4 fili", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-c17ed4adf0be.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:20", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options", "summary": "Cullinan Therapeutics director Mittie Doyle was granted 21,781 stock options at an exercise price of $13.55 per share. The options will vest in full on the earlier of June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This trans", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-967ea913abc1.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:20", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) director receives stock options for 25,319 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUXVUY3FSZ01lQ0g0X0ZuS2VkaXpPYTRpTXlYTHFtUVNjVUpGT0pqb05HQi1saEpOa3ZESmlpY2d5ZEE2YmhpZmNwdk5FcWtKNmtkbUdRSmhxNlgxeWhwYy1TTFd6SU9YNnlFd2R5UTcyNVk5WDQ2WUgzMUEyVFRkcjd2S2VSWktNLWFkTEpsZVBPRzJ3Vk1hZWE3VWVRbl9RRDJKeEo4OGJiVVNVd2x5R1JBOG1BMU9zb1o0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting", "summary": "Cullinan Therapeutics (NASDAQ: CGEM) shareholders elected two Class III directors for three-year terms, ratified KPMG LLP as the independent registered public accounting firm, and approved an advisory vote on executive compensation at their annual meeting. The biotech company has", "url": "https://ng.investing.com/news/sec-filings/cullinan-therapeutics-shareholders-elect-directors-and-approve-proposals-at-annual-meeting-93CH-2561721", "source_name": "Investing.com Nigeria", "published_at": "2026-06-17T16:39:35", "published_display": "17 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM)", "summary": "Cullinan Therapeutics director David D. Meek was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the date of the company's next annual meeting, contingent on his continued service as a director. This gr", "url": "https://www.stocktitan.net/sec-filings/CGEM/form-4-cullinan-therapeutics-inc-insider-trading-activity-9ec69de66175.html", "source_name": "Stock Titan", "published_at": "2026-06-17T10:11:04", "published_display": "17 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay", "summary": "Cullinan Therapeutics (NASDAQ: CGEM) shareholders held their Annual Meeting on June 16, 2026, where they elected two Class III directors, Nadim Ahmed and Stephen Webster, to three-year terms. They also ratified KPMG LLP as the independent registered accounting firm for 2026 and a", "url": "https://www.stocktitan.net/sec-filings/CGEM/8-k-cullinan-therapeutics-inc-reports-material-event-07fbcc8a3cd7.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:33", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (CGEM) Movement", "summary": "Cullinan Oncology Inc. (NASDAQ: CGEM) is showing weak near and mid-term sentiment but a strong long-term outlook, according to AI models. The article details three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss l", "url": "https://news.stocktradersdaily.com/news_release/40/Avoiding_Lag:_Real-Time_Signals_in_CGEM_Movement_061426091002_1781442602.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-14T09:10:00", "published_display": "14 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOamQtSnd6XzhTTmUwQmlPc2ZmV1VZUzVjbDRQUC15a3Fua0FVOE5zWk5VQmRQTHczbWJnTlBpSkF3RXZoblRsa2hNUUZFSEIzb3p1OWVYdVFkVWdPT08zbUhwbXRHR0FUN29TUlRKVU5hUjBYU3NNcTBjY2tiazh5bk84b0RCakUzWEdUNC1R?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Cullinan Therapeutics, Inc. Reports Material Event", "summary": "Cullinan Therapeutics (NASDAQ: CGEM) has reported early-stage clinical data for its T cell engager programs CLN-978 and velinotamig, targeting autoimmune diseases. CLN-978 showed robust efficacy, including remission in a rheumatoid arthritis patient, and velinotamig demonstrated ", "url": "https://www.stocktitan.net/sec-filings/CGEM/8-k-cullinan-therapeutics-inc-reports-material-event-f74cc68f68cd.html", "source_name": "Stock Titan", "published_at": "2026-06-11T01:40:29", "published_display": "11 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics reports promising autoimmune trial data", "summary": "Cullinan Therapeutics announced promising initial clinical data for its dual-targeting T-cell engager, CLN-978, showing its potential in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company reported clinical remissions and B-cell ", "url": "https://grafa.com/en/news/united-states/cgem-cullinan-immunology-data-2026", "source_name": "grafa.com", "published_at": "2026-06-10T15:38:51", "published_display": "10 Jun 2026 15:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cullinan-therapeutics-reports-early-positive-121201214.html", "source_name": "MT Newswires", "published_at": "2026-06-10T12:12:01+00:00", "published_display": "10 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan reports clinical data for autoimmune drug candidates", "summary": "Cullinan Therapeutics Inc. reported promising clinical data for two T cell engager drug candidates, CLN-978 and velinotamig, targeting autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis. Despite a recent stock decline, the company saw positive patient ", "url": "https://m.uk.investing.com/news/stock-market-news/cullinan-reports-clinical-data-for-autoimmune-drug-candidates-93CH-4721558?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-10T12:38:51", "published_display": "10 Jun 2026 12:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases", "summary": "Cullinan Therapeutics announced new clinical data from its T cell engager programs targeting CD19 (CLN-978) and BCMA (velinotamig) for autoimmune diseases. CLN-978 showed potential for immune reset and clinical remissions in systemic lupus erythematosus (SLE) and rheumatoid arthr", "url": "https://www.stocktitan.net/news/CGEM/cullinan-therapeutics-shares-new-clinical-data-across-its-portfolio-vfdmuw4ody73.html", "source_name": "Stock Titan", "published_at": "2026-06-10T11:10:44", "published_display": "10 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Shares New Clinical Data Across Its", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxQcG1LSHREWWRGQU9lZGxMTWF6dkMwNkNTcGthYUVpREI1dWIxU0wyUk9pU3hhX0wwOWxfcnVkVERNWnE4Sm9jVVVpNnNPTHF5VWx4TUp0VzVMVzI5clBJVGYydnNzVW9vcExyNkVhdlZjM0NfYzZveWU5TnlOUm5MVUQtY2NLdHpfb0dPb1hmUXNZZlJfQ01IVDBSdzR3Ql9zVEQ0MkY5eXg0bThaWUFsYWRnYWJQclh6WndaRTdUX2s0Z2J1VVFOZ2ZqbmxYM29CbzlzbWlpTnBoV05aaTZxTHpmRlVKRjB3NGZMV3hqWGctZm9aZ3A3WE44YzBIX0o1dkM0YUVzd0p0YjhoMEJIUzFWV3ZzZjJjVWVPaG1ScmxSaVd3S3ZvdmdaY3pQSHM3VWlDLVlRYkM?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data", "summary": "Cullinan Therapeutics reported initial Phase 1 data for CLN-978, a T cell engager, in treatment-refractory systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), showing meaningful clinical and biologic signals. In SLE, 71% of patients achieved a significant reduction ", "url": "https://www.stocktitan.net/sec-filings/CGEM/8-k-cullinan-therapeutics-inc-reports-material-event-0b963e9bf286.html", "source_name": "Stock Titan", "published_at": "2026-06-08T13:39:46", "published_display": "08 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress", "summary": "Cullinan Therapeutics presented initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress, demonstrating clinical benefit and remission in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The data showed deep, ", "url": "https://www.globenewswire.com/news-release/2026/06/06/3307681/0/en/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-t-cell-engager-at-the-eular-2026-congress.html", "source_name": "GlobeNewswire", "published_at": "2026-06-06T09:40:48", "published_display": "06 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in CGEM Response", "summary": "This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), identifying a near-term strong sentiment potentially shifting to neutral mid-term and positive long-term. It highlights an exceptional 63.5:1 risk-reward setup targeting a 16.9% gain with minimal risk and provides three", "url": "https://news.stocktradersdaily.com/news_release/1/Discipline_and_Rules-Based_Execution_in_CGEM_Response_060326074002_1780486802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-03T07:40:00", "published_display": "03 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEM - Cullinan Therapeutics Inc Stock Price and Quote", "summary": "Cullinan Therapeutics Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing oncology and immuno-oncology therapies. The article provides detailed financial data, analyst ratings, and a comprehensive list of recent company news and insider transactions, i", "url": "https://finviz.com/stock?t=CGEM", "source_name": "Finviz", "published_at": "2026-05-26T19:10:39", "published_display": "26 May 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cullinan-therapeutics-host-immunology-day-110000381.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:00:00+00:00", "published_display": "26 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Gets FDA Orphan Drug Designation for CLN-049 in Acute Myeloid Leukemia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cullinan-therapeutics-gets-fda-orphan-114216412.html", "source_name": "MT Newswires", "published_at": "2026-05-19T11:42:16+00:00", "published_display": "19 May 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cullinan-therapeutics-receives-fda-orphan-110000684.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Cullinan Therapeutics (NASDAQ:CGEM) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQVlB0VGQxek9BX0ItdG4xRW5URHlRUUU3N3BIV3Z1eFhELWNTcmpkTkg3b1JZckpKQ3BYenBTUHBuaUVFMm42ZndTdkdZZjFrVnZfVERiWFNnTEdFNk83azlaSkI2bEVCVjlOLXdzbnktcDMzeEI4UTNzUzNLWWIxNDE4Ym5EZEZ0SlZWQURIT0Y1bTY4SmxpRnpRTnlaZ3BvWFNXQ1ZNaThoaElrekRrZVZPejd2Nnl1SkVRSjZhRGdlb1FQNS1ldmdqRWo5WHdMQjdhTFF6V0YyYUoxV0xHXzlXcTdQSVdkUlHSAe8BQVVfeXFMUGF6U19SOUloWWtLcC01Rm1FaUNXam1DaExMc0c5LXl3aWNnUlgzd2RqR1hBa2dkOFpYSHVPUTlLN3lLTVlWY21ILU8yS2lObE5uR19RMVlIeFlWOHpEVXdTZjVpajVFVldNb3dRWjk2ZlJmNjFRaWI3aWMxd0JURHVUYzQ0RWFGZ3BZU0NKV1hvamZJMTBWNGdlVXlRV1RHeFJPZGk1cl9XZHNGalp4eWlZLVBUeWJoN2lLMkZIS1BLVVBLOWxSa0xJZzdYbk1mNjA0YmhycXpGNjhGSlBNemNnSlo0bVlRdDMwU1A5bjQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNWVlYcFJXTzB5QmdFZVYzZDdqYmpZSU81cEJXbXlMcG1mNzlXNVJud25oRWlWQTh6YmNKekdIUnBXZnB5ck9IbTBVYjZHN0lNMFhNNklqQU1BeUdaZkJPRFNhbXJRXzNBRlNIdmtKMUkyZmJVMmE4UFFaN2hQdWRLZDJsY0VaM1c0eVl5VlZHcmZOSEluX0RMMVNFRl9vUFQ2R0hiS1FoNUhRekI0NEE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOamdub0ZtNFF1cEhESEVyWkRjZmFvd0JlVjBBUmxWQ0pNZTFEVUNJMzJ3cDVBaVdGOHdybmlWcnNsTzk0Z1hucXFfcFVpVEctV1JCRFh2eWRkODN2UzJyN3N1VG96bFNmSUQ5b3d0YzVJcUhOV29JM3BMNDFIbHFjRnBRR29oVUJ3akthNGVOZzIyQQ?oc=5", "source_name": "Market source", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lynx1 capital buys Cullinan Therapeutics (CGEM) shares for $2.1m", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMHBJMlVIa1lDMVRLd0JnLU5iaGtqaGZGLTNVZVNiZV9UWDNHRF9TN1Fyeks4eHI1Y0h1M0xuR2w2V1NwNFpWWUJVelAyenRaaFJhSGk1WS13NmRRSlFaaUlReEVReXJ2Q0puMzhDZU5QQVQ0SEpOQjM2ZmhJMy05aEVZV0pVTEYyTXYwRjVRZ1NxOW5OLVhRX1AxZGdtX0V3SUlhNmJKZUp2MEhMSXlGQkNkaVA3a2ZZUjF1ZlFJbm40VzQ?oc=5", "source_name": "Investing.com", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 49, "sentiment_summary": {"positive": 16, "negative": 1, "neutral": 32, "score": 57, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 19.4, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 10}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 18.13, "latest_week": "2026-07-10", "one_week_move": 2.8, "four_week_move": 32.3, "twelve_week_move": 20.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.608235, "market_dynamics_buy_signal": false, "relative_strength": 39.391457, "fair_value_gap": 44.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.1969, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.8% over one week, +32.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 6}, {"label": "Stock Traders Daily", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "TradingView", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 10}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.8% over one week, +32.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Cullinan CSO sells shares, exercises options | CGEM Insider Trading"}], "updated_at": "2026-07-16T05:41:44.410579+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}